Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from MorphoSys US Inc.

Clinical Vignette Series™: How Will You Leverage Recent Evidence in Relapsed/Refractory DLBCL Settings?

Release Date: October 30, 2020
Expiration Date: October 30, 2021

Activity Overview

Diffuse large B-cell lymphoma (DLBCL) is among the most common forms of non-Hodgkin lymphoma with an estimated 28,000 cases diagnosed in the US each year. Historically, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been the standard of care for patients with DLBCL; and while R-CHOP is associated with an approximate 60% cure rate, 40% of patients are either refractory to R-CHOP or will relapse following treatment response. Accordingly, there is a growing armamentarium of treatments available for the management of relapsed/refractory DLBCL, including anti-CD19 antibodies, chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates, and nuclear transport inhibitors. With expanding treatment options comes the challenge of determining best practices for patient care and making evidence-based treatment decisions.

This online Clinical Vignette Series educational activity consists of clinical cases and video clips featuring short, expert interviews with oncologists providing evidence-based guidance and perspectives on the management of patients with relapsed/refractory DLBCL who are ineligible for transplant. The overarching goal of this program is to offer you expert opinions on typical patients with DLBCL that you can integrate immediately into your practice.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from MorphoSys US Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with diffuse large B-cell lymphoma (DLBCL). Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with DLBCL are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess current standards of care in the management of patients with DLBCL and unmet medical needs in therapy
  • Integrate evidence from landmark clinical trials among patients with relapsed/refractory DLBCL in the context of clinical scenarios
  • Identify approaches to diagnose and manage treatment-related toxicities among patients with DLBCL
  • Discuss emerging therapies and ongoing clinical trials for patients with relapsed/refractory DLBCL

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Christopher R. Flowers, MD, MS, FASCO
Christopher R. Flowers, MD, MS, FASCO
Professor, Department Chairman (Lymphoma/Myeloma)
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, TG Therapeutics. Consultant: AbbVie, Bayer, Celgene (unpaid), Denovo Biopharma, Genentech/Roche (unpaid), Gilead, Karyopharm, OptumRx, Pharmacyclics/ Janssen, Spectrum.

Kami Maddocks, MD
Kami Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The James Cancer Hospital at The Ohio State University
Columbus, OH

Disclosures: Consultant: Celgene, Karyopharm, MorphoSys, Pharmacyclics.

Loretta J. Nastoupil, MD
Loretta J. Nastoupil, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Celgene, Genentech, Janssen, Merck, TG Therapeutics. Consultant: Celgene, Genentech, Gilead, Janssen, Juno, Novartis, TG Therapeutics, Spectrum.

Jason Westin, MD, MS, FACP
Jason Westin, MD, MS, FACP
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Curis, Forty Seven, Genentech, Janssen, Kite, MorphoSys, Novartis, Unum. Consultant: AstraZeneca, Bristol Myers Squibb, Curis, Genentech, Janssen, Kite, MS Pharma, MorphoSys, Novartis.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
2930
Filter By